‘A New Era’: What Next For CRISPR Gene Editing After First Approval?
Analysts, Companies And Researchers Share Their Thoughts On The Field
Emerging out of a landmark 2023, CRISPR companies and researchers are pushing in vivo therapies and other approaches closer to the clinic and potential approval.
